Parasitology Research

, Volume 98, Issue 6, pp 545–549 | Cite as

The efficacy of human schistosomicide treatment may depend on the rate of transmission

  • Nelmar García
  • Gina Isturiz
  • Silvia Aular
  • Renzo Nino IncaniEmail author
Original Paper


The efficacy of different treatment protocols in humans infected with Schistosoma mansoni at sites with different transmission conditions was evaluated by the disappearance of anti-worm intestine IgM antibodies in an indirect fluorescence antibody test (IgM-IFT) and anti-egg antibodies in the circumoval precipitin test (COPT). Patient sera coming from sites of active low transmission (ALT), active high transmission (AHT) and low interrupted transmission (LIT) from Venezuela were studied. Chemotherapy protocols were (1) ALT, 60 mg/kg praziquantel (Pzq60); (2) AHT, one dose of 40 mg/kg Pzq followed by one dose of 20 mg/kg oxamniquine for one group and one dose of 40 mg/kg Pzq alone for the other group; (3) LIT, one dose of 40 mg/kg Pzq repeated every 3 months up to three doses. Cure rates occurred mostly between 3 and 12 months with the exception of Pzq60-ALT where it was evident before 3 months. Higher cure rates were evident in both places of low transmission (ALT and LIT) and the lowest in the AHT regardless of the treatment protocol. Cure was more evident with COPT compared to IgM-IFT. The rate of serological cure appears then to depend on the previous state of transmission. The differential cure rate evaluated by both techniques is probably due to the persistence of antibodies against antigens in different stages of the parasite.


Schistosomiasis Treatment Transmission rate Praziquantel Oxamniquine COPT Immunofluorescence 



The basic clinical and epidemiological work in the communities of Los Naranjos and Seitifero was part of two undergraduate theses of the medical doctors Ruth Salas, Ingrid Sánchez, Ronald Rodríguez and Francisco García. The team for laboratory and field work, in addition to the authors and those already mentioned, responsible for handling the communities studied and obtaining human biological samples and parasite antigens were (1) Bioanalist Marta Eblen, Lab Technicians María de los Angeles Pinto, Lorena Medina, Yanett Saez, María Simons and Sinecio Rivas (from Universidad de Carabobo, Valencia; (2) Dr. Lisbeth Loaiza, Bioanalists Haydee Fuentes and Marietta Díaz, Lab Technicians Angélica Méndez and Lourdes Sánchez, Sanitary Inspectors Pedro Velásquez Gómez, Douglas González, Carlos Vera and John Córdoba (from INSALUD-Carabobo state); (3) Engineer Carlos Balzán, Drs. Trina Camejo and Carmen Sierra, Bioanalist Lourdes Sánchez, Lab Technicians Yesenia Soler and Ana Uzcátegui, Sanitary Inspector Alexis Guevara (from the Dirección de Endemias Rurales, Maracay) and (4) Dr. Italo Cesari, MS Diana Ballén, Bioanalist Leidy Mendoza (from the Instituto Venezolano de Investigaciones Científicas, Caracas). Our gratitude also to Profs. Gustavo Morales (INIA-FONAIAP, Maracay) and José A. García (Universidad de Carabobo) for advice with the statistical analysis. The work carried out comply with current Venezuelan laws.


  1. Alarcón de Noya B, Cesari IM, Losada S, Colmenares C, Balzán C, Hoebeke J, Noya O (1997) Evaluation of alkaline phosphatase immunoassay and comparison with other methods in areas of low transmission of schistosomiasis. Acta Trop 66:68-78Google Scholar
  2. Alarcón de Noya B, Colmenares C, Lanz H, Caracciolo MA, Losada S, Noya O (2000) Schistosoma mansoni: immunodiagnosis is improved by sodium metaperiodate which reduces cross-reactivity due to glycosylated epitopes of soluble egg antigen. Exp Parasitol 95:106–112CrossRefPubMedGoogle Scholar
  3. Alarcón de Noya B, Ruiz R, Colmenares C, Losada S, Cesari IM, Toro J, Noya O (2002) Schistosomiasis mansoni in areas of low transmission: epidemiological characterization of Venezuelan foci. Mem Inst Oswaldo Cruz 97(Suppl I):5–10PubMedGoogle Scholar
  4. Appriou M, Ben Younes R, Tribouley-Duret J, Tribouley J (1989) Étude par la réaction d’immunofluorescence des anticorps dirigés contre les antigènes de l’épithélium intestinal de Schistosoma mansoni. IV. Étude du pouvoir bloquant sur l’immunité d’un anticorps monoclonal de classe IgM. Ann Parasitol Hum Comp 61:435–446Google Scholar
  5. Branchini MLM, Pedro RJ, Dias LCS, Deberaldini ER (1982) Double-blind clinical trial comparing praziquantel with oxamniquine in the treatment of patients with schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 24:315–321PubMedGoogle Scholar
  6. Chitsulo L, Engels D, Montresor A, Savioli L (2000) The global status of schistosomiasis and its control. Acta Trop 77:41–51CrossRefPubMedGoogle Scholar
  7. Coelho PMZ, Ribeiro F, Mello RT, Lima e Silva FC, Nogueira-Machado, JA (1998) Activity of oxamniquine at skin, pulmonary and sexual maturation phases, on a Schistosoma mansoni strain (R1) previously reported as resistant at the adult phase. Mem Inst Oswaldo Cruz 93(Suppl I):267–268CrossRefPubMedGoogle Scholar
  8. Danso-Appiah A, De Vlas SJ (1999) The quantitative effects of praziquantel on Schistosoma mansoni infection in selective population chemotherapy: a meta-analysis. VII International Symposium on Schistosomiasis. Río de Janeiro, BrazilGoogle Scholar
  9. Delgado VS, Suarez DP, Cesari IM, Incani RN (1992) Experimental chemotherapy of Schistosoma mansoni with praziquantel and oxamniquine: differential effect of single or combined formulations of drugs on various strains and on both sexes of the parasite. Parasitol Res 78:648–654CrossRefPubMedGoogle Scholar
  10. Flores SI, Fuentes HV, Aular SM, Guevara MC, Incani RN (1995) Diagnosis of schistosomiasis mansoni using the indirect fluorescent antibody test with paraffin sections of adult worms as antigens. Acta Cient Venez 46(Supl. 1):166Google Scholar
  11. García FA, Aular SM, Loaiza LC, Balzán C, Incani RN (1997) Frequency and morbidity of schistosomiasis mansoni in a community traditionally endemic, Seitifero-Manuare valley, south Carabobo state. Acta Cient Venez 48(Supl. 1):172Google Scholar
  12. Incani RN (1987) The Venezuelan experience in the control of schistosomiasis mansoni. Mem Inst Oswaldo Cruz 82(Suppl. 4):89–93Google Scholar
  13. Incani RN, Lara O, Leañez C, Maldonado M, Martínez CJ, García JA (1987) Schistosomiasis mansoni at low transmission rate in a rural village south Valencia lake. III. Chemotherapy with oxamniquine or praziquantel. International Symposium on Schistosomiasis, Río de Janeiro, Brazil. S55Google Scholar
  14. Incani RN, Aular S, Eblen M, Mendoza L, Ballen D, Cesari I (1999) Mass chemotherapy with praziquantel as a tool for control of schistosomiasis mansoni in a community of low transmission. Acta Cient Venez 50(Supl. 2):341Google Scholar
  15. Kanamura HY, Dias LCS, Silva RM, Glasser CM, Patucci RMJ, Vellosa SAG, Antunes JLF (1998) A comparative epidemiologic study of specific antibodies (IgM and IgA) and parasitological findings in an endemic area of low transmission of Schistosoma mansoni. Rev Inst Med Trop Sao Paulo 40:85–91PubMedGoogle Scholar
  16. Leopold G, Ungethum W, Groll E, Diekmann HW, Nowak H, Wegner DHG (1978) Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. Eur J Clin Pharmacol 14:281–291CrossRefPubMedGoogle Scholar
  17. Mott KE, Dixon H (1982) Collaborative study on antigens for immunodiagnosis of schistosomiasis. Bull World Health Organ 60:729–753PubMedGoogle Scholar
  18. Oliver-González, J (1954) Anti-egg precipitins in sera of humans infected with Schistosoma mansoni. J Infect Dis 95:86–91PubMedGoogle Scholar
  19. Pujol FH, Cesari IM (1990) Antigenicity of adult Schistosoma mansoni alkaline phosphatase. Parasite Immunol 12:189–198PubMedGoogle Scholar
  20. Salas RM, Sánchez IB, Rodríguez R, Aular SM, Loaiza LC, Balzán C, Incani RN (1997) Schistosomiasis in the valley of Los Naranjos, Carabobo state, a focus of high transmission. I. Basic epidemiology. Acta Cient Venez 48(Supl. 1):171Google Scholar
  21. Santiago N, Srour S, Vargas Y, Violante C, Ibañez M, García JA, Incani RN (1988) Schistosoma mansoni: fluorescent antibody test and circumoval precipitin test as criteria of cure in infected patients. Acta Cient Venez 39(Supl.1):139Google Scholar
  22. Savioli L, Renganathan E, Montresor A, Davis A, Behbehani K (1997) Control of schistosomiasis—a global picture. Parasitol Today 13:444CrossRefPubMedGoogle Scholar
  23. Silva LC, Zeitune JMR, Rosa-Eid LMF, Lima DMC, Antinelli RH, Christo CH, Saez-Alquezar A, Carboni AC. (1986) Treatment of patients with schistosomiasis mansoni: a double blind clinical trial comparing praziquantel with oxamniquine. Rev Inst Med Trop Sao Paulo 28:174–180PubMedGoogle Scholar
  24. Silva RM, Silva MIPG, Vellosa SAG, Kanamura HY (1992) Pesquisa de anticorpos IgM contra tubo digestivo do verme para o diagnóstico da esquistossomose mansônica. Rev Bras Patol Clin 28:39–42Google Scholar
  25. Zwingenberger K, Nogueira Queiroz JA, Poggensee U, Alencar JE, Valdegunas J, Esmeralda F, Feldmeier H (1987) Efficacy of oxamniquine, praziquantel and a combination of both drugs in schistosomiasis mansoni in Brazil. Rev Inst Med Trop Sao Paulo 29:305–311PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Nelmar García
    • 1
  • Gina Isturiz
    • 1
  • Silvia Aular
    • 1
  • Renzo Nino Incani
    • 1
    Email author
  1. 1.Departamento de Parasitología, Facultad de Ciencias de la SaludUniversidad de CaraboboValenciaVenezuela

Personalised recommendations